Sofie Qiao News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sofie qiao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sofie Qiao Today - Breaking & Trending Today

Vivace Therapeutics Raises $30M in Series C Financing – FinSMEs


Vivace Therapeutics, Inc., a San Mateo, CA-based small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, closed a $30m Series C financing.
The round was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. In conjunction with the funding, Dr. Norman Zhou of Boxer Capital joined the board of directors at Vivace.
The company intends to use the funds to advance its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.
Led by Sofie Qiao, Ph.D., President and Chief Executive Officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. The company is pursuing several first-in-class drug candidates to treat human carcinomas of high unmet medical need. . ....

Norman Zhou , Vivace Therapeutics Inc , Vivace Therapeutics , San Mateo , Boxer Capital , Sofie Qiao , Chief Executive Officer , நார்மன் ஜூ , விவேஸ் சிகிச்சை இன்க் , விவேஸ் சிகிச்சை , சான் மாடேயொ , குத்துச்சண்டை வீரர் மூலதனம் , தலைமை நிர்வாகி அதிகாரி ,

Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway


Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway
News provided by
Share this article
Share this article
SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/  Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C financing. The company anticipates advancing its clinical candidate into first-in-human studies in early 2021, targeting tumors dependent on activated YAP.  The Series C financing was led by Boxer Capital with participation from new investor RA Capital Management alongside existing investor Canaan Partners. With the financing, Dr. Norman Zhou of Boxer Capital has joined the board of directors at Vivace. ....

San Francisco Bay , United States , San Diego , Aaron Davis , Jake Simson , Norman Zhou , Boxer Capital , Vivace Therapeutics Inc , Boxer Capital Of Tavistock Group , Tavistock Group , Vivace Therapeutics , Sofie Qiao , Chief Executive Officer , San Francisco Bay Area , Canaan Partners , Wuxi Healthcare Ventures , Cenova Capital , Sequoia Capital China , சான் பிரான்சிஸ்கோ வளைகுடா , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஆரோன் டேவிஸ் , ஜேக் சிம்சன் , நார்மன் ஜூ , குத்துச்சண்டை வீரர் மூலதனம் , விவேஸ் சிகிச்சை இன்க் ,